Background
Osteosarcoma, the most common type of primary bone cancer, is a malignant neoplasm notorious for its high aggressiveness and early metastatic potential [
1]. However, little is known about the signaling pathways that are crucial for its progression, and the molecular biology of osteosarcoma remains poorly understood. Histologically, osteosarcoma is categorized into several different types, including osteoblastic osteosarcoma, chondroblastic osteosarcoma, fibroblastic osteosarcoma and giant cell-rich osteosarcoma. The giant cell-rich osteosarcoma is the rare subtype of primary osteogenic sarcoma, and, to the best of our knowledge, only 18 cases have been reported in the literature to date [
2]. Its name derives from the existence of multinucleated giant cells within the tumor tissues, which were generally believed to be osteoclast-like tumor cells [
2]; yet their exact identity still remains to be elucidated.
A class of disintegrins and metallproteinases, known as ADAMs, have been shown to participate in a variety of signaling events that are aberrant in cancers as well as during tumor progression [
3]. ADAM10, a member of the ADAM family, has been found to be upregulated in many cancers, including ovarian, colon and prostate cancers [
4,
5]. Overexpression of ADAM10 promotes the growth of oral squamous cell carcinoma and gastric carcinomas, whereas downregulation of its expression reduces proliferation of carcinoma cells [
6,
7]. However, the role of ADAM10 in osteosarcoma is still unclear.
As a membrane-bound sheddase, ADAM10 cleaves a variety of cell surface proteins, including Notch receptors [
8,
9]. In the canonical Notch signaling pathway, Notch receptors interact with membrane-anchored ligands, followed by sequential proteolytic cleavage by ADAM10 and presenilin within the transmembrane, thus releasing the Notch intracellular domain (NICD), which enters the nucleus and regulates a cohort of Notch-dependent genes. Although aberrant Notch receptor expression has been reported in osteosarcoma [
10] and manipulation of the Notch pathway has been shown to play a crucial role for
Hes1 (a Notch-dependent gene) in osteosarcoma invasion and metastasis [
11,
12], whether the ADAM10–Notch1 signaling axis is particularly involved in osteosarcoma is unknown.
CD31 is a member of the immunoglobulin (Ig) gene superfamily and plays an important role in a number of endothelial cell functions, including angiogenesis, inflammation, integrin activation and intercellular adhesion [
13‐
15], which could also be employed by tumor cells for their progression. Indeed, on the basis of their immunohistochemical staining of primary and metastatic osteosarcoma samples, Arihiro
et al. suggested that the formation of metastatic foci of osteosarcoma cells in other bones might be regulated by CD31 to promote endothelial cell migration [
16]. Nevertheless, the role of CD31 in nonmetastatic osteosarcoma has not yet been revealed.
The goal of our present study was to investigate the expression of ADAM10, Notch1, CD31 and tartrate-resistant acid phosphatase (TRAP) in nonmetastatic osteosarcoma tissue and their respective contributions to tumor progression.
Methods
Tissue chips
Paraformaldehyde-fixed, paraffin-embedded human osteosarcoma tissue chip slides were purchased from US Biomax (Rockville, MD, USA). Each slide contained 40 duplicate samples of osteosarcoma tissues, and pathological stages included IA (n = 3), IB (n = 5), IIA (n = 10) and IIB (n = 22), according to the Musculoskeletal Tumor Society Staging System. This study was approved by the ethics committee of Daping Hospital of the Third Military Medical University.
Reagents and antibodies
Mouse anti-human CD31 monoclonal antibody (Ab), rabbit anti-human ADAM10 (cytoplasmic domain) polyclonal Ab and rabbit anti-human activated Notch1 NICD polyclonal Ab were all purchased from Abcam (Cambridge, UK). Isotype-specific control Abs were also obtained from Abcam and were used to control staining specificity. Fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse IgG Ab (ZSGB-BIO, Beijing, China) and cyanine 3 (Cy3)-conjugated goat anti-rabbit IgG Ab (Beyotime Institute of Biotechnology, Jiangsu, China) were used as secondary Abs. Antifade mounting medium was also obtained from Beyotime Institute of Biotechnology.
Immunohistological and immunofluorescent staining
Paraffin tissue sections were deparaffinized in xylene, rehydrated through graded ethanol series and washed in 10 mM phosphate-buffered saline (PBS), pH 7.4. Hematoxylin and eosin (H&E) staining was performed according to a standard protocol. The histological types were assessed by an experienced pathologist specializing in osteosarcoma diagnosis. For immunofluorescent staining, antigen retrieval was performed by incubating tissue sections for 20 minutes in 0.01 M sodium citrate buffer, pH 6.0, and heated in a microwave oven, then sections were permeabilized with 0.1% Triton X-100. After blocking with 5% bovine serum albumin/PBS for 30 minutes, three sequential slides were then incubated with anti-CD31 Ab, anti-ADAM10 (cytoplasmic domain) Ab and anti activated Notch1 (NICD) Ab, respectively. For double-immunofluorescence staining, two additional sequential slides were incubated with either anti-CD31 Ab (mouse anti-human) plus anti-ADAM10 Ab (rabbit anti-human) or anti-CD31 Ab plus anti-NICD Ab (rabbit anti-human), respectively. Isotype-specific control Abs were used to test staining specificity. Slides were incubated overnight at 4°C. After being washed with PBS, slides were stained with secondary FITC anti-mouse Ab and Cy3 anti-rabbit Ab for 30 minutes at room temperature (RT). Afterward, nuclei were stained with 4′,6-diamidino-2-phenylindole (DAPI) for 10 minutes at RT. Images were obtained using the MRC-600 digital confocal laser scanning system (Bio-Rad Laboratories, Hercules, CA, USA).
TRAP/DAPI staining
TRAP staining was performed on deparaffinized and rehydrated sections using the Acid Phosphatase, Leukocyte (TRAP) Kit (Sigma-Aldrich, St Louis, MO, USA) according to the manufacturer’s instructions. DAPI staining was performed afterward as mentioned above to visualize the nuclei.
Data analysis
Acquired images were exported and merged using Image-Pro Plus version 6.0 software (MediaCybernetics, Rockville, MD, USA). NICD and CD31 density percentages were measured as the percentage of positive FITC signal area against the whole field area under 100× magnification as described by Connor
et al. [
17]. ADAM10-positive tumor cells were counted in ADAM10/DAPI merged images under the same magnification, and analysis was performed with tools in Image-Pro Plus software. Statistical differences were determined using a two-tailed, unpaired Student’s
t-test.
Discussion
Although ADAM10 has been found to be upregulated in many cancers [
4,
5], its expression in tumors with mesenchymal origin (particularly osteosarcoma) remains unknown. Herein we show that ADAM10 was generally expressed in osteosarcoma tumor cells in a condensed and polarized pattern. The level of ADAM10 in tumor cells significantly increases as osteosarcoma progresses, as well as in osteoblastic osteosarcoma tissue, suggesting that it might play a role in osteosarcoma tumor progression and the pathological development of osteoblastic osteosarcoma. As ADAM10 is a major sheddase of Notch receptors [
8,
9], and because researchers in recent studies have discovered that Notch signaling was activated in human osteosarcoma and may play a role in tumor invasion and metastasis [
11,
18,
19], we speculate that ADAM10 might participate in osteosarcoma progression through the shedding of Notch receptors and activation of the Notch signaling pathway.
Currently, there is no systematic evaluation comparing Notch expression in clinical osteosarcoma between different pathological stages. Hence, we analyzed activated Notch1 (NICD) expression from stages IB to IIB at the protein level and found no significant alteration in NICD density. Therefore, as one of four members in the mammalian Notch receptor family, Notch1 might not be the Notch receptor responsible for osteosarcoma progression. Similarly, Tanaka
et al. found that expression of Notch1 mRNA was decreased in specimens from human osteosarcoma biopsies compared with normal bone tissues [
20].
Previous studies have shown that CD31 expression was significantly correlated between primary and metastatic osteosarcomas [
16], but the correlation between nonmetastatic groups is not clear. In our present study, we found that variation in the density of CD31 was not significantly associated with osteosarcoma staging from IA to IIB, although there was a trend toward increased CD31 expression as osteosarcoma progressed.
The expression of CD31 and activation of Notch1 did not dramatically contribute to osteosarcoma progression overall. In the specific case of multinucleated tumor cells in giant cell-rich osteosarcoma, however, the expression of CD31 may facilitate the adhesion of these tumor cells to endothelial cells. Migration between endothelial cells may also occur via homophilic interactions between CD31 and CD31 and heterophilic interactions between CD31 and α
vβ
3 integrin, which has been shown to be expressed in both osteosarcoma cells and endothelial cells [
14,
21,
22], thus promoting tumor cell migration. Given the fact that these tumor cells also coexpress ADAM10 and activated Notch1, ADAM10/Notch1 signaling might also participate in this process, as recent studies have demonstrated that ADAM10 and Notch1 could promote the migration of a variety of tumor cells, both cooperatively [
23] and individually [
24,
25]. Furthermore, the absent staining of TRAP and positive staining of CD31 in multinucleated giant cells suggest that these cells are not osteoclasts, but rather a type of angiogenic tumor cells in which ADAM10/Notch1 signaling is activated.
Conclusion
In our present study, we examined the expression of CD31, ADAM10, Notch1 and TRAP in nonmetastatic osteosarcoma tissue chips. We found that only ADAM10 expression was significantly correlated with tumor progression and osteoblastic osteosarcoma development. Our results also suggest that multinucleated giant cells are not osteoclasts, but angiogenic tumor cells in which ADAM10/Notch1 signaling is activated and might be implicated in tumor cell migration. The results of this study imply heterogeneity in osteosarcoma between metastatic and nonmetastatic types and complexity within nonmetastatic types. It also highlights ADAM10 as a potential target for the biological intervention of nonmetastatic osteosarcoma.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
ZR designed the study, carried out the immunohistological and immunofluorescence studies and TRAP staining experiments, collected and analyzed the data and drafted the manuscript. NDJ participated in the immunofluorescence experiment. TY helped to analyze the data. NB and WAM participated in the study design and revised the manuscript. All authors read and approved the final manuscript.